Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Nektar Therapeutics’s stock clocked out at $57.13, up 4.16% from its previous closing price of $54.85. In other words, the price has increased by $4.16 from its previous closing price. On the day, 0.7 million shares were traded. NKTR stock price reached its highest trading level at $57.365 during the session, while it also had its lowest trading level at $53.545.
Ratios:
To gain a deeper understanding of NKTR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 1.96 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on November 26, 2025, initiated with a Buy rating and assigned the stock a target price of $102.
On June 24, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $6.50 to $120.
BTIG Research reiterated its Buy rating for the stock on June 24, 2025, while the target price for the stock was revised from $60 to $100.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 25 ’25 when Zalevsky Jonathan sold 1,157 shares for $54.28 per share. The transaction valued at 62,802 led to the insider holds 18,971 shares of the business.
Wilson Mark Andrew sold 630 shares of NKTR for $34,196 on Nov 25 ’25. The Chief Legal Officer now owns 21,585 shares after completing the transaction at $54.28 per share. On Nov 25 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 2,207 shares for $54.28 each. As a result, the insider received 119,796 and left with 54,245 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 1162114944 and an Enterprise Value of 1058985984. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.56 while its Price-to-Book (P/B) ratio in mrq is 13.20. Its current Enterprise Value per Revenue stands at 16.917 whereas that against EBITDA is -7.833.
Stock Price History:
The Beta on a monthly basis for NKTR is -0.95, which has changed by 2.5849674 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $66.92, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is -2.70%, while the 200-Day Moving Average is calculated to be 107.61%.
Shares Statistics:
It appears that NKTR traded 1.01M shares on average per day over the past three months and 638330 shares per day over the past ten days. A total of 20.34M shares are outstanding, with a floating share count of 20.05M. Insiders hold about 1.44% of the company’s shares, while institutions hold 70.47% stake in the company. Shares short for NKTR as of 1763078400 were 1813497 with a Short Ratio of 1.79, compared to 1760486400 on 1731971. Therefore, it implies a Short% of Shares Outstanding of 1813497 and a Short% of Float of 9.08.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Nektar Therapeutics (NKTR) in the stock market.The consensus estimate for the next quarter is -$2.59, with high estimates of -$2.59 and low estimates of -$2.59.
Analysts are recommending an EPS of between -$7.97 and -$11.59 for the fiscal current year, implying an average EPS of -$9.78. EPS for the following year is -$11.86, with 2.0 analysts recommending between -$11.6 and -$12.12.
Revenue Estimates
In. The current quarter, 8 analysts expect revenue to total $10.44M. It ranges from a high estimate of $15.81M to a low estimate of $6.9M. As of. The current estimate, Nektar Therapeutics’s year-ago sales were $29.18MFor the next quarter, 8 analysts are estimating revenue of $10.1M. There is a high estimate of $12.5M for the next quarter, whereas the lowest estimate is $6M.
A total of 8 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $49.24M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $43.85M. In the same quarter a year ago, actual revenue was $98.43MBased on 8 analysts’ estimates, the company’s revenue will be $42.13M in the next fiscal year. The high estimate is $54.44M and the low estimate is $24M.
